Cartesian Therapeutics says Phase 2 retreatment data for Descartes-08 in myasthenia gravis supports ongoing Phase 3 AURORA trial

Cartesian Therapeutics said new Phase 2 retreatment data for Descartes-08 in myasthenia gravis supports its ongoing Phase 3 AURORA trial. The findings were presented at the MGFA Scientific Session at AANEM in Orlando.

Detected & updated continuously · Source: Nebula